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Abstract
Background: Adulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for
adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved
survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight
into the extent to which changes in clinical trials have translated into better survival on the population level.
Methods: Data were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer
registries in Germany. Patients age 15–69 diagnosed with ALL were included. Period analysis was used to estimate 5-year
relative survival (RS).
Results: Overall 5-year RS was estimated at 43.4% for Germany and 35.5% for the US (p = 0.004), with a decrease in survival
with increasing age. Survival was higher in Germany than the US for men (43.6% versus 37.7%, p = 0.002) but not for women
(42.4% versus 40.3%, p.0.1). Five-year RS estimates increased in Germany and the US between 2002 and 2006 by 11.8 and
7.3 percent units, respectively (p = 0.02 and 0.04, respectively).
Conclusions: Survival for adults with ALL continues to be low compared with that for children, but a substantial increase in
5-year survival estimates was seen from 2002 to 2006 in both Germany and the US. The reasons for the survival differences
between both countries require clarification.
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Introduction
Acute lymphoblastic leukemia (ALL) is a rare cancer, especially
in adults. Survival estimates for patients with ALL are high for
children, both in clinical trials [1] and population based studies
[2], but decrease rapidly with age [3,4], and adult ALL is
frequently fatal [5,6]. Aggressive treatment of ALL has demon-
strated increased survival in young and middle aged adult patients
in clinical trials [5]. However, these changes have not yet been
confirmed on the population level.
Because of the rarity of ALL in adults, there are relatively few
population level data available concerning survival of patients with
ALL and most available data come from the Surveillance,
Epidemiology, and End Results (SEER) database in the United
States (US) [2–4,6,7] and cancer registries from Nordic countries
[8,9]. In the past, estimates of population level survival for patients
with leukemia in Germany have been limited to aggregate data for
all forms of leukemia [10] due to lack of a unified, high quality
population level database. Recently, a collaborative effort between
the German Cancer Research Center and population based
cancer registries in Germany covering 11 federal states has allowed
for evaluation of population level survival for rare cancers in
Germany, including evaluation of age and sex specific survival
[11].
Here, we examine survival of adults diagnosed with ALL in
Germany by age and gender and compare survival to that seen in
patients with ALL in the US.
Methods
Data Sources
A detailed description of the cancer registries from which data
were obtained has been published previously [11]. Briefly, data
extracted from cancer registries throughout Germany covering 11
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federal states, representing a total base population of 33 million
people, were included (Table 1). Patients age 15 or older with a
primary diagnosis of ALL (ICD-10 code C91.0) in 1997–2006 and
with mortality follow up through December, 2006 were included.
Cancer topography, morphology, and behavior were originally
coded in accordance with the International Classification of
Disease for Oncology (ICD-O)-3 guidelines and later converted
into ICD-10 using ‘IARCcrgTools’ [12]. Patients with both B-cell
and T-cell acute lymphoblastic leukemia are covered under this
diagnostic code in ICD-10. For some registries, data were
available starting from later years only. Cases both with and
without preceding cancers were included. Because there were data
quality issues for patients age 70+ in some of the German
registries, only data for patients age 15–69 were included. In order
to compare population level survival for ALL in Germany with
survival in the United States (US), data from the Surveillance,
Epidemiology, and End Results (SEER13) database were analyzed
[13]. The same inclusion criteria as for patients from the German
cancer registries were applied for the same time period. The
SEER13 database includes data from 13 regional cancer centers in
the US, covering a population of about 39 million people. Centers
are chosen for inclusion based on their high quality and
epidemiologically interesting population groups. The SEER
population is considered to be similar to the general US
population with respect to most sociodemographic characteristics
[13], although it may be more affluent than average and may have
slightly higher than average survival for some cancers [14].
Ethics
The data contained in the databases under study is stripped of
all sensitive identifying information prior to being made available
to researchers. Thus, no additional specific informed consent was
required for analysis of the anonymised data in this project.
Written consent was neither possible nor desirable as it would
represent a link to individual patients and thus constitute a risk of
disclosure that would not otherwise exist.
Statistical Methods
Five-year relative survival estimates for the time period 2002–06
were calculated using period analysis [15]. Period analysis, first
introduced in 1996 [16], provides more up-to-date survival
estimates than traditional cohort based analysis. This is achieved
by ‘‘left truncation’’ of all observations at the beginning of the
period of interest (in our case: the beginning of 2002). In
particular, it has been shown by empirical evaluation, that period
estimates of 5-year relative survival for a given period quite closely
predict 5-year relative survival later observed for patients
diagnosed during the period of interest [16–18]. Age-adjusted
survival estimates were derived by computing weighted sums of
age-specific survival estimates using weights according to the
proportion of cases in various age groups (15–24, 25–39, 40–59,
and 60–69) in Germany.
Age intervals were chosen based on frequency of ALL at various
ages and for potentially clinically significant age breaks, i.e.
patients over age 60 are much less likely to be eligible for a
traditional hematopoietic stem cell transplant, which may affect
survival. In addition, in the US, universal health insurance is
available only to patients age 65 and older (Medicare) and thus
older patients may have a relative survival advantage at that age
compared to younger patients who may be uninsured. Because
survival in ALL varies with age and gender, we examined survival
by major age groups and by gender. Differences in survival
between men and women, as well as between patients in Germany
and the US, were tested for statistical significance, overall and by
single age groups, using model-based period analysis [19].
Additionally, model-based period analysis was employed to
estimate most recent changes in 5-year relative survival within
the 2002–2006 period.
Because the number of cases reported to cancer registries by
death certificate only (DCO) in the German database was still
high, the impact of the exclusion of DCO cases in the computation
of the survival estimates was estimated by providing plausibility
ranges for survival estimates. The plausibility range is derived by
computing relative survival once after exclusion of DCO cases
(upper limit of the estimate) and once by multiplying the relative
survival estimate obtained after exclusion of DCO cases by one
minus the percentage of DCO cases (lower limit). The latter
estimate was suggested by Berrino et al. [20] to account for the
overoptimistic estimate of relative survival after exclusion of DCO
cases. Brenner and Holleczek [21] have shown that these two
estimates provide a plausibility range for true survival, as the
former estimate is expected to overestimate true survival, and the
latter estimate is expected to underestimate true survival under
plausible assumptions.
Relative survival was calculated as the ratio of actual survival to
expected survival. Expected survival was estimated according to
the Ederer II method [22] using national life tables stratified by
age, sex, and calendar year obtained from German Federal
Statistical Office. Relative survival estimates for the US patients
were calculated using US sex, age, calendar year, and race specific
life tables published by the Center for Disease Control (CDC) [23].
All calculations were carried out using SAS software (version
9.2), using macros developed for standard and modeled period
analysis [19,24].
Results
Overall, 1295 patients age 15–69 were identified in the German
database. After exclusion of DCO cases (9.3%), 1175 cases
remained for analysis. Median age at diagnosis was 39 years (for
patients age 15–69 at diagnosis), with some variability between
registries, ranging from 36 in Rhineland-Palatinate to 42 years in
Saarland (Table 1). The percentage of DCO cases varied between
databases, ranging from 1.5% in Saarland to 24% in Rhineland-
Palatinate.
Within the SEER database, 2314 patients were identified using
the same criteria as above and after exclusion of 7 (0.3%) cases
identified by DCO, 2307 remained for analysis. Median age at
diagnosis for patients in the SEER database was 37 years for
patients age 15–69 at time of diagnosis.
Overall age standardized five-year relative survival was 43.4%
in Germany and 35.5% in the US (Table 2). There was a trend
towards higher 5-year survival in Germany for each age group,
which reached significance overall and for ages 40–59 at +7.9
percent units and +15.9 percent units, respectively. Plausibility
ranges, which take potential overestimation of survival due to the
higher proportions of DCO cases in Germany into account,
suggest that the latter are unlikely to explain the higher survival
estimates in Germany compared to the US as the lower ends of the
plausibility range were still higher than the US estimates in each
case.
Interestingly, most of the difference in survival seems to be
related to differences in survival for men. When survival was
examined by gender and age, men had a higher five year relative
survival in Germany (Table 3). The survival advantage of male
patients from Germany was statistically significant overall and for
ages 40–59 at +5.9 and +19.0 percent units, respectively. No
statistically significant difference in survival was seen for women at
ALL Survival in Germany and the US
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any age and there was a trend towards lower survival in Germany
for ages 15–39 (Table 3). It should be noted that there was a large
difference in the point estimate of survival for women age 40–59 in
Germany versus the US at +12.6 percent units, but the difference
was not statistically significant, possibly due to the small number of
cases. Survival decreased with age in both men and women. This
finding was statistically significant for all populations except for
women age 50–59 compared to 60–69.
Because race may be used as a proxy for socioeconomic status
and may convey risk of sub-optimal treatment in the US and there
are known differences in survival by race for patients with acute
leukemias in the US [6], we examined survival only for patients
listed as ‘‘white’’ in the US as well. Full results are shown in
table S1. Overall there was little change in the pattern seen when
all patients were included, with continued better survival for
patients in Germany, especially for men, but with larger
confidence intervals and thus fewer differences that were
statistically significant.
In order to examine recent changes in survival of patients with
ALL, survival in 2002 and 2006 was compared in each country. In
Germany, there was a significant improvement in survival between
2002 and 2006, by +11.8 (p = 0.02) percent units (Table 4).
In the US, there was a statistically significant increase, at +7.3
percent units (Table 5).
In both countries, the increase in survival was limited to male
patients, at +20.9 percent units and +9.7 percent units in Germany
and the US, respectively. Survival for women with ALL was
virtually unchanged in either country between 2002 and 2006. In
both countries, survival for men was lower than for women in
2002 but similar to or higher than for women in 2006.
Discussion
Five year survival for young and middle aged adults with ALL
was higher in Germany than in the US overall. There was a trend
towards higher survival estimates for all ages, even though this
trend only reached significance for the age group 40–59. Survival
estimates were higher in Germany for men but not for women.
Survival estimates were higher overall in 2006 than in 2002 in
both countries, but the increase was restricted to men in each
country. Survival decreased rapidly with age in both countries.
The reasons for the differences observed between Germany and
the US are not obvious. Treatment guidelines, which recommend
aggressive combination chemotherapy with or without hemato-
poietic stem cell transplantation for young and fit patients, are
similar in both countries [25,26]. The use of tyrosine kinase
inhibitors is recommended for Philadelphia chromosome positive
patients in each country. Additionally, there is no routine
screening test available for ALL, making differences in the timing
of diagnosis unlikely. It is possible that lack of health insurance,
possibly leading to delays in treatment or sub-optimal treatment,
may contribute to lower survival in the US, but the data do not
show a large difference in survival at younger ages in the US as
one might expect if lack of insurance were a major issue [27,28].
Female gender is considered a good prognostic indicator for
pediatric patients with ALL [29,30]. However, these differences
could be at least partly explained by differences in biological
features of the ALL [30]. The literature is less clear with respect to
the role of gender in survival of adults with ALL, with some studies
showing better results for female patients, others finding better
outcomes for male patients [31,32]. In our study, men had much
worse prognosis than women at the beginning of the period of
investigation (2002) in both countries, but men seem to have
caught up and even achieved higher survival than women in
Germany in 2006, possibly reflecting greater benefit of newer
therapies or new applications of existing therapies (i.e. the use of
tyrosine kinase inhibitors in BCR_Abl positive leukemias or the
use of pediatric protocols in young adults) to men than women.
However, given the rarity of the condition, some amount of
random fluctuation can not be ruled out.
Table 1. Patients diagnosed with acute lymphoblastic leukemia at age 15–69 included in this analysis.
Registry
Population
base (million)
Years
Included
Cases
registered
% DCO
(excluded)
Cases in
the analysis
Median age
at diagnosis
% Microscopically
confirmed
Bavariaa 8.13 2002–06 205 8.3 188 38.0 100.0
Brandenburg 2.55 1997–2006 175 11.4 155 37.0 100.0
Bremen 0.66 1998–2006 34 5.9 32 36.5 96.9
Hamburg 1.75 1997–2006 111 4.5 106 36.5 100.0
Mecklenburg-
Vorpommern
1.69 1997–2006 115 12.2 101 38.0 100.0
Lower Saxony 7.98 2001–06 185 10.3 166 40.0 97.5
North Rhine-
Westphaliaa
2.62 1997–2004 94 7.4 87 39.0 98.8
Rhineland-
Palatinatea
0.52 1998–2006 25 24.0 19 36.0 89.5
Saarland 1.04 1997–2006 67 1.5 66 42.0 98.5
Saxony 4.25 1997–2006 215 7.4 199 40.0 98.5
Schleswig-
Holsteina
1.85 1999–2006 69 18.8 56 38.5 100.0
Total
SEER
33.04
39 1997–2006
1295
2314
9.3
0.3
1175
2307
39.0
37.0
99.0
99.3
DCO=death certificate only.
aSelected administrative districts only.
11 German registries, 1997–2006.
doi:10.1371/journal.pone.0085554.t001
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Increasing age is generally considered a poor prognostic
indicator in acute leukemia and we found that, as expected,
survival decreased rapidly with increasing age in Germany and the
US. Patients age 15–24 had a greater than 10 percent units better
chance of 5-year survival than patients in the next older age group
of 25–39. This may reflect use of more aggressive treatment in
younger patients, higher probability of good prognosis leukemias
in younger patients, or some combination of these two factors.
Previous studies have found a higher prevalence of poor
prognostic markers, including the Philadelphia chromosome,
among older patients [31,33] as well as a lower prevalence of
good prognostic markers [34]. Additionally, patients over age 25
may not be offered aggressive therapy or may have increased
mortality with aggressive therapy, leading to an overall decrease in
survival [35]. Because of the relatively small number of cases
available for analysis, even with the large databases examined, we
were not able to determine whether the observed changes in
survival during the period of investigation were distributed equally
at all ages or if some age groups experienced greater or lesser
change.
Strengths of this study include the use of large, population based
databases to determine survival estimates and inclusion of data
from a number of registries. This allows for detailed estimates of
survival in a rare tumor such as ALL on the population level.
Population level survival can vary greatly from survival observed
in clinical trials [36], making this information important in
determining the ‘‘real world’’ outcomes of patients with a given
condition. Additionally, the use of the large databases allows for
examination of sub-groups of patients, which may help identify
areas of concern, i.e. patient populations for whom survival is not
changing or is worsening, even as survival improves overall for a
given condition. Finally, the use of period analysis and modelled
period analysis provide the most up-to-date estimates of survival
possible.
In considering our work, several limitations should be consid-
ered. First, despite the use of the large population based databases,
the relative rarity of ALL makes it difficult to analyze survival
patient subgroups with precision. For example, a number of
relatively large differences in point estimates of survival were not
statistically significant due to small numbers and resultant large
confidence intervals. This makes the possibility of a type two error
high. Second, the databases used for this analysis did not contain
important information on therapy, such as chemotherapy,
hematopoietic stem cell transplantation, or inclusion in clinical
trials. Therefore, no conclusions can be drawn with respect to
possible treatment differences between Germany and the US.
Third, in the absence of a national death index in Germany,
most cancer registries rely on record linkage with vital statistics
from the region that they cover and may miss deaths among
patients who move out of the region. Number of patients lost to
follow up is not directly assessed by most registries with the
exception of two registries: Hamburg and Bremen. Nevertheless,
previous validation studies have suggested potential overestimation
of survival due to deaths missed by migration to be very small [11].
Specifically, the effect of migration was directly measured for two
registries covering Hamburg and Bremen and patients who
emigrated were censored at the date of emigration. If these
patients were instead listed as alive, the rate of apparent survival
was raised by less than 1% unit. The effect of migration on larger
regional databases is expected to be even lower.
There is a theoretical concern about incomplete inclusion of
patients given that some registries have 100% microscopically
confirmed cases which might suggest incomplete registration of
cases. However, elimination of the registries with 100% micro-
scopically confirmed cases did not materially change the results
(data not shown) and the percentage of microscopically confirmed
cases in the SEER data is also quite high (99.3%), suggesting that
any bias that might be present is present equally in each registry.
Finally, the higher proportion of DCO notifications in Germany
might affect survival estimates. We aimed to address this concern
by providing plausibility ranges for the relative survival estimates
in Germany. As the lower end of the plausibility range by far
exceeded the survival estimates for the US in most cases, it is
unlikely that the major survival differences between both countries
are due to differences in data quality and completeness of case
ascertainment.
In summary, higher 5-year relative survival estimates were
observed on the population level for adults with ALL in Germany
compared to the US. Some increase in survival was seen in each
country, but survival estimates did not reach those observed in
childhood for either country. Survival decreased with age. A major
survival disadvantage of male patients seems to have been
overcome in the period of investigation during which a strong
increase in survival was seen among male, but not among female
patients.
Table 2. Five year relative survival of patients with acute lymphoblastic leukemia in Germany and the US in 2002–06, overall and
by age.
Germany US
Age N RS SE Plausibility range N RS SE Diff P (Model)
15–24 322 59.2 3.8 56.9–59.2 680 54.9 2.8 +4.3 0.5232
25–39 280 47.7 4.2 43.0–47.7 580 42.3 3.0 +5.4 0.4491
40–59 331 40.0 3.9 35.7–40.0 759 24.1 2.3 +15.9 0.0041
60–69 242 21.8 4.5 18.9–21.8 288 17.7 3.5 +4.1 0.2725
Overalla 1175 43.4 2.0 39.8–43.4 2307 35.5 1.4 +7.9 0.0040
N= number of cases.
RS = 5-year relative survival.
SE = standard errors.
Diff = difference in survival between Germany and the United States.
aAge-standardized.
doi:10.1371/journal.pone.0085554.t002
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